Growth Hormone & Igf Research最新文献

{"title":"Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease","authors":"Zvi Laron ,&nbsp;Haim Werner","doi":"10.1016/j.ghir.2023.101548","DOIUrl":"10.1016/j.ghir.2023.101548","url":null,"abstract":"<div><p><span>Insulin like growth factor I (IGF</span><img><span>I) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia<span> treatment should be considered.</span></span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"71 ","pages":"Article 101548"},"PeriodicalIF":1.4,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10228282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of CTCF and FOXA1 with androgen and IGF pathways in men with localized prostate cancer","authors":"Rachel Barker ,&nbsp;Kalina Biernacka ,&nbsp;Georgina Kingshott ,&nbsp;Alex Sewell ,&nbsp;Paida Gwiti ,&nbsp;Richard M. Martin ,&nbsp;J. Athene Lane ,&nbsp;Lucy McGeagh ,&nbsp;Anthony Koupparis ,&nbsp;Edward Rowe ,&nbsp;Jon Oxley ,&nbsp;Claire M. Perks ,&nbsp;Jeff M.P. Holly","doi":"10.1016/j.ghir.2023.101533","DOIUrl":"10.1016/j.ghir.2023.101533","url":null,"abstract":"<div><h3>Aims</h3><p>To examine associations between the transcription factors CCCTC-binding factor (CTCF) and forkhead box protein A1<span><span> (FOXA1) and the androgen receptor (AR) and their association with components of the insulin-like growth factor (IGF)-pathway in a cohort of men with localized </span>prostate cancer.</span></p></div><div><h3>Methods</h3><p><span>Using prostate tissue samples collected during the Prostate cancer: Evidence of Exercise and Nutrition Trial (PrEvENT) trial (</span><em>N</em><span><span> = 70 to 92, depending on section availability), we assessed the abundance of CTCF, </span>FOXA1, AR, IGFIR, p-mTOR, PTEN and IGFBP-2 proteins using a modified version of the Allred scoring system. Validation studies were performed using large, publicly available datasets (TCGA) (</span><em>N</em> = 489).</p></div><div><h3>Results</h3><p>We identified a strong correlation between CTCF and AR staining with benign prostate tissue. CTCF also strongly associated with the IGF<img>IR, with PTEN and with phospho-mTOR. FOXA1 was also correlated with staining for the IGF-IR, with IGFBP-2 and with staining for activated phosphor-mTOR. The staining for the IGF-IR was strongly correlated with the AR.</p></div><div><h3>Conclusion</h3><p>Our findings emphasise the close and complex links between the endocrine controls, well known to play an important role in prostate cancer, and the transcription factors implicated by the recent genetic evidence.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"69 ","pages":"Article 101533"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10040202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of growth response and adverse reaction according to growth hormone dosing strategy for children with short stature: LG Growth Study","authors":"Kyungchul Song ,&nbsp;Mo Kyung Jung ,&nbsp;Jun Suk Oh ,&nbsp;Su Jin Kim ,&nbsp;Han Saem Choi ,&nbsp;Myeongseob Lee ,&nbsp;Junghwan Suh ,&nbsp;Ahreum Kwon ,&nbsp;Hyun Wook Chae ,&nbsp;Ho-Seong Kim","doi":"10.1016/j.ghir.2023.101531","DOIUrl":"10.1016/j.ghir.2023.101531","url":null,"abstract":"<div><h3>Objective</h3><p>Growth hormone (GH) dosage in children is conventionally determined either by body weight (BW) or body surface area (BSA). However, there is no consensus on the calculation method for proper GH treatment dose. We aimed to compare growth response and adverse reactions between BW- and BSA-based GH treatment doses for children with short statures.</p></div><div><h3>Design</h3><p>Data from 2284 GH-treated children were analyzed. Distributions of BW- and BSA-based GH treatment doses and their association with growth response parameters, including changes in height, height standard deviation score (SDS), body mass index (BMI), and safety parameters, such as changes in insulin-like growth factor (IGF)-I SDS and adverse events, were investigated.</p></div><div><h3>Results</h3><p><span><span>The mean BW-based doses were close to the recommended dose's<span> upper limit in participants with GH deficiency and </span></span>idiopathic short stature, while they were below the recommended dose </span>in patients<span> with Turner syndrome (TS). As age and BW increased, BW-based dose decreased, whereas BSA-based dose increased. Gain in height SDS was positively associated with BW-based dose in the TS group and negatively associated with BW in all groups. Despite having a lower BW-based dose, the overweight/obese groups had a higher BSA-based dose and higher frequencies of children with high IGF-I and adverse events than those of the normal-BMI group.</span></p></div><div><h3>Conclusions</h3><p>In children of older age or with high BW, BW-based doses can be overdosed in terms of BSA. and BW-based dose positively correlated with height gain only in the TS group. BSA-based doses represent an alternative dosing strategy in children who are overweight/obese.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"69 ","pages":"Article 101531"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9666379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise combined with lysine-inositol vitamin B12 promotes height growth in children with idiopathic short stature","authors":"Fengping Sun ,&nbsp;Liqin Chao ,&nbsp;Junxia Zhang ,&nbsp;Xiaoli Pan","doi":"10.1016/j.ghir.2023.101535","DOIUrl":"10.1016/j.ghir.2023.101535","url":null,"abstract":"<div><h3>Objective</h3><p>This study was aimed to systematically determine the effect of exercise combined with lysine-inositol vitamin B12<span> (VB12) therapy on the height of children with idiopathic short stature (ISS).</span></p></div><div><h3>Methods</h3><p>Sixty children with ISS were randomly divided into observation and control groups (<em>N</em><span> = 30). Each group was given lysine-inositol VB12 oral solution (10 mL bid). Simultaneously, the observation group exercised following the “ISS exercise instruction sheet”. The height (H), growth velocity (GV), height standard deviation score (HtSDS) and other indicators were compared after 6 and 12 months of intervention, respectively. After 12 months of intervention, the biochemical indicators of the two groups, together with the correlation between the average days of exercise per week and average minutes of exercise per day, GV and serum growth hormone were analyzed.</span></p></div><div><h3>Results</h3><p><span><span>After 6 and 12 months of treatment, the GV, serum </span>GHRH, GHBP, GH, IGF-1, and IGFBP-3 levels in the observation group were significantly higher than those in the control group, and HtSDS was significantly lower than that in the control group (</span><em>P</em>&lt;0.01). After 12 months of treatment, the height of the observation group was significantly higher than that of the control group (<em>P</em>&lt;0.05). There was no significant difference in the biochemical indicators between two groups (<em>P</em>&gt;0.05). Average days of exercise per week and average minutes of exercise per day were positively correlated with GV and GHBP levels. Serum GHRH, GH, IGF-1, and IGFBP-3 levels were negatively correlated. Average minutes of exercise per day were negatively correlated with GV and GHBP levels. Serum GHRH, GH, IGF-1, and IGFBP-3 levels were positively correlated.</p></div><div><h3>Conclusion</h3><p>Regular and moderate stretching exercises combined with lysine-inositol VB12 can effectively promote height growth of children with ISS, which is clinically safe. The mechanism promotes serum GHRH, GHBP, GH, IGF-1, and IGFBP-3 levels.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"69 ","pages":"Article 101535"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of growth hormone therapy in children with Noonan syndrome","authors":"Giorgio Sodero ,&nbsp;Clelia Cipolla ,&nbsp;Lucia Celeste Pane ,&nbsp;Linda Sessa ,&nbsp;Elena Malavolta ,&nbsp;Federica Arzilli ,&nbsp;Chiara Leoni ,&nbsp;Giuseppe Zampino ,&nbsp;Donato Rigante","doi":"10.1016/j.ghir.2023.101532","DOIUrl":"10.1016/j.ghir.2023.101532","url":null,"abstract":"<div><p>Patients with Noonan syndrome typically have a target height &lt;2 standard deviations compared to the general population, and half of the affected adults remain permanently below the 3rd centile for height, though their short stature might result from a multifactorial etiology, not-yet fully understood. The secretion of growth hormone (GH) following the classic GH stimulation tests is often normal, with baseline insulin-like growth factor-1 (IGF-1) levels at the lower normal limits, but patients with Noonan syndrome have also a possible moderate response to GH therapy, leading to a final increased height and substantial improvement in growth rate. Aim of this review was to evaluate both safety and efficacy of GH therapy in children and adolescents with Noonan syndrome, also evaluating as a secondary aim the possible correlations between the underlying genetic mutations and GH responses.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"69 ","pages":"Article 101532"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9658146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decreased insulin-like growth factor-1 expression in response to mechanical loading is associated with skeletal muscle anabolic resistance in cancer cachexia","authors":"Mitsunori Miyazaki ,&nbsp;Atsushi Sawada ,&nbsp;Daisuke Sawamura ,&nbsp;Susumu Yoshida","doi":"10.1016/j.ghir.2023.101536","DOIUrl":"10.1016/j.ghir.2023.101536","url":null,"abstract":"<div><h3>Objective</h3><p><span>Cachexia<span> is a systemic metabolic syndrome characterized by loss of body weight and </span></span>skeletal muscle<span> mass during chronic wasting diseases, such as cancer. Skeletal muscle in cancer cachexia is less responsive to anabolic factors including mechanical loading; however, the precise molecular mechanism is largely unknown. In this study, we examined the underlying mechanism of anabolic resistance in skeletal muscle in a cancer cachexia model.</span></p></div><div><h3>Methods</h3><p><span>CD2F1 mice (male, 8 weeks old) were subcutaneously transplanted (1 × 10</span>⁶<span> cells per mouse) with a mouse colon cancer-derived cell line (C26) as a model of cancer cachexia. Mechanical overload of the plantaris muscle<span> by synergist tenotomy was performed during the 2nd week and the plantaris muscle was sampled at the 4th week following C26 transplantation.</span></span></p></div><div><h3>Results</h3><p>The hypertrophic response of skeletal muscle (increased skeletal muscle weight/protein synthesis efficiency and activation of mechanistic target of rapamycin complex 1<span> signaling) associated with mechanical overload was significantly suppressed during cancer cachexia. Screening of gene expression profile and pathway analysis using microarray revealed that blunted muscle protein synthesis was associated with cancer cachexia and was likely induced by downregulation of insulin-like growth factor-1 (IGF-1) and impaired activation of IGF-1-dependent signaling.</span></p></div><div><h3>Conclusions</h3><p>These observations indicate that cancer cachexia induces resistance to muscle protein synthesis, which may be a factor for inhibiting the anabolic adaptation of skeletal muscle to physical exercise in cancer patients.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"69 ","pages":"Article 101536"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9667913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth hormone-releasing hormone antagonists counteract hydrogen peroxide – induced paracellular hyperpermeability in endothelial cells","authors":"Nektarios Barabutis ,&nbsp;Agnieszka Siejka ,&nbsp;Mohammad S. Akhter","doi":"10.1016/j.ghir.2023.101534","DOIUrl":"10.1016/j.ghir.2023.101534","url":null,"abstract":"<div><p><span><span>Growth Hormone-Releasing Hormone (GHRH) is a hypothalamic peptide which regulates the release of Growth Hormone from the anterior </span>pituitary gland, and has been involved in inflammatory processes. On the other hand, GHRH antagonists (GHRHAnt) were developed to counteract those effects. Herein we demonstrate for the first time that GHRHAnt can suppress hydrogen peroxide (H</span>₂O₂<span><span>) - induced paracellular hyperpermeability in bovine pulmonary artery endothelial cells. Increased production of </span>reactive oxygen species<span> (ROS) and barrier dysfunction have been associated with the development of potentially lethal disorders, including sepsis and acute respiratory distress syndrome (ARDS). Our study supports the protective actions of GHRHAnt in the impaired endothelium, and suggests that those compounds represent an exciting therapeutic possibility towards lung inflammatory disease.</span></span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"69 ","pages":"Article 101534"},"PeriodicalIF":1.4,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9721036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The coexistence of newly diagnosed acromegaly with primary empty sella: More frequent than expected?","authors":"Emre Urhan ,&nbsp;Aysa Hacioglu ,&nbsp;Izzet Okcesiz ,&nbsp;Zuleyha Karaca ,&nbsp;Canan Sehit Kara ,&nbsp;Kursad Unluhizarci","doi":"10.1016/j.ghir.2022.101521","DOIUrl":"10.1016/j.ghir.2022.101521","url":null,"abstract":"<div><h3>Objective</h3><p>We investigated the coexistence of newly diagnosed acromegaly with primary empty sella (ES), which is considered to be a rare association, and the impact of ES on the laboratory, radiological and prognostic status of acromegaly.</p></div><div><h3>Design</h3><p><span>Acromegaly patients diagnosed and followed-up between 2012 and 2021 were included. Empty sella was defined as the pituitary gland<span> and adenoma filling &lt;50% of the </span></span>sella turcica on preoperative T1 magnetic resonance imaging (MRI).</p></div><div><h3>Results</h3><p><span>102 acromegalic patients (45 male, 57 female, 45.5 ± 12.8 (range: 20–70 years) were included and data of a median 3 years (range: 0.5–9 years) were presented. ES was detected in 19 (18.6%) patients and 4 had complete and 15 had partial ES. Although not significant, adenoma size and residual adenoma on MRI on postoperative 3rd month, and disease remission<span><span> at last control were lower in acromegaly with ES than in acromegaly without ES, while the rate of female gender and remission on postoperative 3rd month were higher. While preoperative serum prolactin and nadir GH responses to </span>OGTT were significantly lower </span></span>in patients<span> with ES, there was no difference in terms of other pituitary hormones among both groups.</span></p></div><div><h3>Conclusion</h3><p>The present study revealed the coexistence of newly diagnosed acromegaly with primary ES at a rate of nearly 20% which is more frequent than expected and this association is not rare. The presence of ES was not associated with any preoperative/postoperative pituitary hormone levels and remission status, except lower preoperative prolactin and nadir GH responses to OGTT.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"68 ","pages":"Article 101521"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10729793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of two prediction models in a clinical setting to predict growth in prepubertal children on recombinant growth hormone","authors":"Helena-Jamin Ly ,&nbsp;Anders Lindberg ,&nbsp;Hans Fors ,&nbsp;Jovanna Dahlgren","doi":"10.1016/j.ghir.2023.101523","DOIUrl":"10.1016/j.ghir.2023.101523","url":null,"abstract":"<div><h3>Objective</h3><p>Prediction models that calculate the growth response in children on recombinant growth hormone (GH) have shown to be helpful tools in deciding who should start treatment, as identifying GH deficiency can be a challenge. The aim of the study is to compare two prediction models; the KIGS (Pfizer International Growth Study) prediction models which are more accessible and the Gothenburg model which has previously been clinically validated.</p></div><div><h3>Design</h3><p>All prepubertal patients who commenced GH treatment at Queen Silvia Children's Hospital in Gothenburg during a 13-year-period were candidates for the study. Children were excluded if suspected syndrome, malignant disease, chronic disease, or poor adherence to treatment were found. The KIGS model and the Gothenburg model were used to make predictions. Data was obtained from medical charts for the period from birth to the end of the first year of treatment. The predicted height outcome was compared against observed.</p></div><div><h3>Results</h3><p>The study included 123 prepubertal children (76 males). The average age at treatment start and standard deviation (SD) was 5.7 (1.8) years. Correlation analyses were performed between predicted growth by both the Gothenburg and KIGS models versus the first year observed growth response showing strong correlations of <em>r</em> = 0.990 and <em>r</em> = 0.991 respectively with studentized residuals of 0.10 (0.81) for the Gothenburg model and 0.03 (0.96) for the KIGS model.</p></div><div><h3>Conclusion</h3><p>We found that both the Gothenburg model and the KIGS model are equivalent when applying to our clinical cohort. Both models are very precise, hence it is encouraged to use either based on accessibility for the clinic.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"68 ","pages":"Article 101523"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9296718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers of growth and carbohydrate metabolism in neonatal rats supplemented with fish oil and/or antioxidants during intermittent hypoxia","authors":"Despoina Myrsini Galetaki ,&nbsp;Charles L. Cai ,&nbsp;Kulsajan S. Bhatia ,&nbsp;Vivian Chin ,&nbsp;Jacob V. Aranda ,&nbsp;Kay D. Beharry","doi":"10.1016/j.ghir.2022.101513","DOIUrl":"10.1016/j.ghir.2022.101513","url":null,"abstract":"<div><h3>Objective</h3><p>Extremely low gestational age neonates (ELGANs) experience frequent intermittent hypoxia<span><span><span> (IH) episodes during therapeutic oxygen. ELGANs exhibit poor postnatal growth<span> requiring lipid supplementation. Lipids are targets of </span></span>reactive oxygen species<span> resulting in lipid peroxidation and </span></span>cell death<span>, particularly in preterm infants with compromised antioxidant systems. We tested the hypothesis that early supplementation with lipids and/or antioxidants promotes growth and influences biomarkers of carbohydrate metabolism in neonatal rats exposed to IH.</span></span></p></div><div><h3>Design</h3><p><span>Newborn rats (</span><em>n</em><span> = 18/group) were exposed to brief hypoxia (12% O</span>₂<span>) during hyperoxia (50% O</span>₂<span><span>), or room air (RA), from birth<span> (P0) to P14 during which they received daily oral supplementation with: 1) fish oil; 2) Coenzyme Q10 (CoQ10) in olive oil; 3) </span></span>glutathione<span><span><span><span><span> nanoparticles (nGSH); 4) fish oil+CoQ10; or 5) olive oil. At </span>P21<span>, plasma samples were assessed for glucose, insulin, glucokinase<span> (GCK), glucagon, glucagon-like peptide (GLP)-1, growth hormone (GH), </span></span></span>corticosterone, and </span>ghrelin. Liver was assessed for </span>histopathology<span><span><span>, apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling, TUNEL stain), and GH, insulin-like growth factor (IGF)-I, </span>GH binding protein (GHBP), and </span>IGF binding protein (IGFBP)-3.</span></span></span></p></div><div><h3>Results</h3><p><span><span>Neonatal IH resulted in decreased liver weight and liver/body weight ratios, as well as hepatocyte swelling, steatosis, and apoptosis, which were attenuated with fish oil, nGSH, and combined fish oil+CoQ10. IH also decreased </span>plasma glucose, insulin, GCK, and ghrelin, but increased GLP-1. All </span>treatments improved plasma glucose in IH, but insulin was higher with CoQ10 and nGSH only. Glucagon was increased with CoQ10, fish oil, and CoQ10 + fish oil, while corticosterone was higher with nGSH and CoQ10 + fish oil. IGF-I and IGFBP-3 were significantly higher in the liver with CoQ10 in IH, while deficits in GH were noted with CoQ10 and fish oil in RA and IH. Treatment with nGSH and combined CoQ10 + fish oil reduced IGF-I in RA and IH but increased IGFBP-3.</p></div><div><h3>Conclusions</h3><p>Neonatal IH impairs liver growth with significant hepatocyte damage. Of all supplements in IH, nGSH and combined fish oil+CoQ10 were most effective for preserving liver growth and carbohydrate metabolism. Data suggest that these supplements may improve poor postnatal organ and body growth; and metabolic dysfunction associated with neonatal IH.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"68 ","pages":"Article 101513"},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10730270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}